Announcements Trials
Browse Landscape

Phase

Phase 2 1Phase 1 1

Status

Completed 2

Sponsor Class

NIH 1INDUSTRY 1

Study Type

Interventional 2

Sponsor

Cancer Type

Breast 7Thoracic 4Head & Neck 3Gastrointestinal 3Sarcoma 2Gynecologic 2Genitourinary 2CNS 2Dermatologic 1

Conditions

Neuroblastoma 42Glioblastoma 38Brain Neoplasms 33Glioma 31Central Nervous System Neoplasms 27Gliosarcoma 22Astrocytoma 22Oligodendroglioma 16Medulloblastoma 13Neoplasms 12Rhabdomyosarcoma 7Osteosarcoma 7Recurrence 6Ependymoma 5Diffuse Intrinsic Pontine Glioma 5Sarcoma, Ewing 4Optic Nerve Glioma 4Ganglioneuroblastoma 4Familial ependymoma 4Breast Neoplasms 4Sarcoma 3Rhabdoid Tumor 3Pinealoma 3Pancreatic Neoplasms 3Neurologic Manifestations 3Neuroectodermal Tumors, Primitive, Peripheral 3Colonic Neoplasms 3Choroid Plexus Neoplasms 3Bone Neoplasms 3Wilms Tumor 2

Interventions

pembrolizumab 3Trastuzumab 2Irinotecan 2Cyclophosphamide 2vocimagene amiretrorepvec 1veliparib 1sacituzumab govitecan 1paclitaxel-Angiopep-2 conjugate 1lenvatinib 1irinotecan sucrosofate 1iniparib 1fludarabine 1depatuxizumab mafodotin 1cabozantinib 1bintrafusp alfa protein, human 1aldesleukin 1Platinum 1Nivolumab 1NVP-BKM120 1N-(2,3-dihydroxypropyl)-1-((2-fluoro-4-iodophenyl)amino)isonicotinamide 1Metformin 1Mebendazole 1Ipilimumab 1Interleukin-2 1Flucytosine 1Doxycycline 1Cisplatin 1Capecitabine 1Atorvastatin 17-hydroxystaurosporine 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Triple Negative Breast Neoplasms × Irinotecan × CNS × Clear all
NCT01173497 2016-03-17

A Study Evaluating INIPARIB in Combination With Chemotherapy to Treat Triple Negative Breast Cancer Brain Metastasis

Sanofi

Phase 2 Completed
44 enrolled
BreastCNS

Brain Neoplasms, Breast Neoplasms, Triple Negative Breast Neoplasms

NCT00031681 2013-09-30

7-Hydroxystaurosporine and Irinotecan Hydrochloride in Treating Patients With Metastatic or Unresectable Solid Tumors or Triple Negative Breast Cancer (Currently Accruing Only Triple-negative Breast Cancer Patients Since 6/8/2007)

National Cancer Institute (NCI)

Phase 1 Completed
41 enrolled
BreastCNSGastrointestinalGenitourinaryGynecologicHead & NeckSarcomaThoracic

Squamous Cell Carcinoma of Head and Neck, Carcinoma, Ovarian Epithelial, Anus Neoplasms, Appendiceal Neoplasms, Bile Duct Neoplasms, Breast Neoplasms, Carcinoma, Non-Small-Cell Lung, Uterine Cervical Neoplasms, Colonic Neoplasms, Esophageal Neoplasms, Gallbladder Neoplasms, Carcinoma, Hepatocellular, Pancreatic Neoplasms, Prostatic Neoplasms, Rectal Neoplasms, Salivary Gland Neoplasms, Stomach Neoplasms, Endometrial Neoplasms, Esthesioneuroblastoma, Olfactory, Gastrointestinal Stromal Tumors, Small Cell Lung Carcinoma, Triple Negative Breast Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡